Balyasny Asset Management
JUNO

Balyasny Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Balyasny Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-120,945
Closed -$5.53M – 2549
2017
Q4 		$5.53M Sell
120,945
-636,141
-84% -$31.7M 0.02% 826
2017
Q3 		$34M Buy
757,086
+582,986
+335% +$19.9M 0.13% 209
2017
Q2 		$5.2M Buy
+174,100
New +$4.3M 0.02% 741

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Balyasny Asset Management's JUNO Position: Q1 2018 in Review

Balyasny Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 120,945 shares — an estimated $5.53M sold.

Balyasny Asset Management first reported a position in JUNO in Q2 2017 and held it in 3 quarters. The position peaked at $34M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Balyasny Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 120,945 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.53M.
  • Balyasny Asset Management first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Balyasny Asset Management's Juno Therapeutics, Inc. position peaked at $34M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.